The Pediatric Brain Tumor Consortium (PBTC) is pleased to announce open, competitive applications for new member institutions. PBTC’s 11 full member institutions are supported by the National Cancer Institute through the Cancer Therapy Evaluations Program (CTEP). New centers will be considered for membership as part of an expansion of the PBTC based upon criteria outlined below. Up to five institutions will be asked to join the Consortium with NCI support. Institutions qualifying for PBTC membership should demonstrate exceptional expertise in pediatric brain tumors with the ability to deliver coordinated multidisciplinary clinical care and conduct relevant laboratory research. Institutions must be based in the United States or Canada and must be members of the Children’s Oncology Group. For more information, see PBTC announcement for new sites .
Application for new membership requires submission of both the application form and a brief protocol concept for a Phase I or II study that may be suitable for development through the PBTC. Using the criteria detailed in the application form, institutions will be chosen to be members of the PBTC based upon the following prioritized selection criteria:
Please send the completed membership application, the study concept, the support letters and biosketches to Arzu Onar-Thomas at email@example.com by 15 May 2020.
For additional information regarding consideration of membership, please contact Ira Dunkel, MD, Chair (firstname.lastname@example.org), Jason Fangusaro, MD, Vice-Chair (email@example.com) or Arzu Onar-Thomas, PhD, Executive Director of the Operations Biostatistics and Data Management Core (firstname.lastname@example.org). Applicants will be notified of the results of the competitive review by August 2020 and new member institutions will officially become part of the PBTC shortly thereafter.